Description

Details of first call money received and listing approval for 19,740 partly paid-up equity shares of Solara Active Pharma Sciences Limited with paid-up value of Rs. 7/- per share.

Summary

Solara Active Pharma Sciences Limited has received listing and trading approval for 19,740 partly paid-up equity shares (Scrip Code: 890202) following receipt of first call money. The shares have a paid-up value of Rs. 7/- per share with ISIN IN9624Z01022 and no lock-in period.

Key Points

  • First call notice sent for 1,19,98,755 partly paid shares on April 07, 2025
  • Reminder notice sent for 6,08,988 shares on July 01, 2025
  • Total first call money received on 1,17,61,546 shares
  • Listing and trading approval received for 1,17,41,163 shares
  • 19,740 shares to be available for trading on resumption
  • 643 shares could not be credited to depositories due to pledge
  • Paid-up value per share: Rs. 7/-
  • ISIN: IN9624Z01022
  • No lock-in period applicable

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

This is an informational circular regarding listing approval. No specific compliance actions required from market participants.

Important Dates

  • April 07, 2025: First call notice sent
  • May 07, 2025: First call money received (1,13,89,767 shares); BSE in-principle approval
  • May 08, 2025: NSE in-principle approval
  • July 01, 2025: Reminder notice sent
  • August 16, 2025: First call money received pursuant to reminder (3,71,779 shares)
  • August 19, 2025: BSE in-principle approval (second tranche)
  • August 21, 2025: NSE in-principle approval (second tranche)
  • January 27, 2026: Communication date to BSE

Impact Assessment

Market Impact: Minimal. The circular involves listing of only 19,740 partly paid-up equity shares, representing a very small fraction of the company’s total equity. This is a routine administrative listing following call money receipt and will have negligible impact on stock price or trading volumes.

Operational Impact: Standard listing procedure with all regulatory approvals obtained from both BSE and NSE. The shares are immediately available for trading with no restrictions or lock-in period.

Impact Justification

Routine listing of small quantity of partly paid-up shares (19,740 shares) following first call money receipt; limited market impact